S. Porkert, “Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma”, Acta Derm Venereol, vol. 101, no. 2, p. adv00383, Feb. 2021.